Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus MOMETASONE FUROATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus MOMETASONE FUROATE.
ARMONAIR DIGIHALER vs MOMETASONE FUROATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARMONAIR DIGIHALER contains fluticasone furoate and umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, modulating gene expression to reduce inflammatory mediators. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors, causing bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, leading to smooth muscle relaxation and bronchodilation.
Mometasone furoate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokines, chemokines, and adhesion molecules involved in inflammation.
2 inhalations (55 mcg each) orally twice daily for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
Inhaled: 110-880 mcg twice daily; Intranasal: 2 sprays (50 mcg/spray) per nostril once daily; Topical: Apply thin film to affected area once daily.
None Documented
None Documented
Terminal elimination half-life of unchanged arformoterol is approximately 26 hours (range 21-30 hours). This supports twice-daily dosing with approximately 2 days to steady state.
The terminal elimination half-life is approximately 5.8 hours (range 4.5–7.5 hours) following intravenous administration; after intranasal or inhalation use, the effective half-life supporting once-daily dosing is derived from receptor binding and local tissue retention.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30%
Mometasone furoate is extensively metabolized in the liver; less than 1% of the dose is excreted unchanged in urine. The metabolites are primarily excreted in feces (~74%) via biliary elimination, with renal excretion accounting for approximately 8–10%.
Category C
Category A/B
Inhaled Corticosteroid
Topical / Inhaled Corticosteroid